EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules

Davide Benedetto Tiz iD, Marco D'Alì iD, Nunzio Iraci iD, Claudio Santi iD, Luca Sancineto iD

Biomolecules · 03.03.2026 · 16 (3) · 381

DOI: 10.3390/biom16030381 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 03.03.2026. Verfasst von Davide Benedetto Tiz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Logic Gates, Department of Chemistry, Faculty of Science, University of Malta, MSD 2080 Msida, Malta. Hauptthemen laut MEDLINE: Halogens, Small Molecule Libraries. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Halogens, particularly fluorine, chlorine, and bromine, play a pivotal role in modern drug discovery and development. Their incorporation into drug molecules significantly influences physicochemical properties, including lipophilicity, metabolic stability, and target binding affinity. Fluorine, the most commonly used halogen, enhances bioavailability and receptor interactions, as seen in several blockbuster drugs. Chlorine and bromine contribute to hydrophobic interactions and modulate pharmacokinetics, while iodine is less frequently utilized due to its larger atomic size and reactivity. The strategic placement of halogens in drug scaffolds has led to the success of numerous FDA-approved pharmaceuticals across therapeutic areas, including oncology, infectious diseases, and central nervous system disorders. This review explores the structure–activity relationships (SAR) of halogen-containing drugs, highlighting recent approvals (2025), their synthesis (with yields, when available), therapeutic use, and, when experimentally available, the interaction with their biological target macromolecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HalogensSmall Molecule LibrariesHumansUnited States Food and Drug AdministrationUnited StatesStructure-Activity RelationshipDrug ApprovalDrug Discovery

Stichwörter der Autor:innen

FDAapproved drugshalogensmedicinal chemistrysynthesis

Substanzen

HalogensSmall Molecule Libraries

Autor:innen und Institutionen

  • Laboratory of Molecular Logic Gates, Department of Chemistry, Faculty of Science, University of Malta, MSD 2080 Msida, Malta.
  • Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina, Italy.
  • Group of Catalysis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy.

ORCID-Profile: Davide Benedetto Tiz, Marco D'Alì, Nunzio Iraci, Claudio Santi, Luca Sancineto

Zitieren

APA

Benedetto Tiz, D., D'Alì, M., Iraci, N., Santi, C., & Sancineto, L. (2026). Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules. Biomolecules, 16(3), 381. https://doi.org/10.3390/biom16030381

Vancouver

Benedetto Tiz D, D'Alì M, Iraci N, Santi C, Sancineto L. Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules. Biomolecules. 2026;16(3):381. doi:10.3390/biom16030381

BibTeX
@article{BenedettoTiz2026,
  author = {Benedetto Tiz, Davide and D'Alì, Marco and Iraci, Nunzio and Santi, Claudio and Sancineto, Luca},
  title = {Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {381},
  doi = {10.3390/biom16030381}
}
Kostenlos starten →